{"id":"administration-of-cimzia","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"10-20%","effect":"Nasopharyngitis"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action prevents the inflammatory effects of TNF, which is involved in the inflammatory process of various autoimmune diseases. By inhibiting TNF, Cimzia reduces inflammation and slows disease progression.","oneSentence":"Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:01.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Crohn's disease"},{"name":"Moderate to severe ulcerative colitis"},{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT00844285","phase":"","title":"SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2009-01-30","conditions":"Crohn's Disease","enrollment":3072},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT01095393","phase":"","title":"National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09-01","conditions":"Rheumatoid Arthritis","enrollment":12500},{"nctId":"NCT01864265","phase":"PHASE3","title":"Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":156},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT01590966","phase":"PHASE3","title":"Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-10-18","conditions":"Axial and Peripheral Spondyloarthritis, Rheumatoid Arthritis","enrollment":41},{"nctId":"NCT02019602","phase":"PHASE1","title":"A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-01","conditions":"Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis","enrollment":37},{"nctId":"NCT00329303","phase":"PHASE2","title":"Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-04","conditions":"Psoriasis","enrollment":71},{"nctId":"NCT00899678","phase":"PHASE2","title":"The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents","status":"TERMINATED","sponsor":"UCB Celltech","startDate":"2009-04","conditions":"Crohn's Disease","enrollment":99},{"nctId":"NCT00993668","phase":"PHASE4","title":"Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09","conditions":"Rheumatoid Arthritis","enrollment":224},{"nctId":"NCT02154425","phase":"PHASE1","title":"A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-09","conditions":"Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis","enrollment":17},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"administration of Cimzia®","genericName":"administration of Cimzia®","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. Used for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}